Tamoxifen-associated vasculitis in a breast cancer patient.

Among women with ER-positive disease, the reduction in the recurrence rate and in the breast cancer death rate are highly significant either after 1–2-year or 5-year use of tamoxifen, but are greater in the latter.

also in 132,142 other papers